Prescribing GLP-1 drugs through teleconsultation: Evaluation of legality
Several digital healthcare platforms in India now offer GLP-1-led weight management programmes for obesity and diabetes, integrating medical consultations, diagnostic assessments, prescription medication and ongoing patient support into a single service model. While this approach may improve access to care, particularly for patients in remote areas or those with limited access to specialist services, it raises an important regulatory question: can chronic conditions such as diabetes and obesity be diagnosed through teleconsultation, and can medicines for those conditions be prescribed without the patient ever being examined in person?
The answer is not necessarily straightforward. While the Telemedicine Practice Guidelines, 2020 recognise teleconsultation as a legitimate mode of healthcare delivery, they also prescribe specific requirements for diagnosis and the prescription of medicines. Understanding how these requirements apply to the diagnosis and ongoing management of chronic conditions is therefore essential to determining the extent to which such digital healthcare models can operate within the existing regulatory framework.
Telemedicine Guidelines Framework
The Telemedicine Practice Guidelines, 2020 (the "Telemedicine Guidelines"), expressly recognise telemedicine as a legitimate mode through which a Registered Medical Practitioner ("RMP") may provide healthcare services. The Guidelines apply to consultations conducted through video, audio and text-based modes of communication.
Importantly, telemedicine does not create a separate or lower standard of medical care. The Guidelines require an RMP to exercise the same professional judgment that would apply in an in-person consultation, while recognising the limitations of remote consultation, for instance,by restricting certain medicines to circumstances where an in-person consultation is required. Further, prescribing through telemedicine involves two separate considerations. The RMP must first be satisfied that there is sufficient clinical information to prescribe the medicine safely. The medicine must also fall within the category permitted for that particular type of consultation. Meeting only one of these requirements may not be sufficient.
Can a Chronic Condition Be Diagnosed Through Teleconsultation?
Under the Guidelines, whether a diagnosis can be made remotely is ultimately a matter of the RMP’s clinical judgment. However, that judgment must be exercised within the following safeguards:
The RMP must decide whether teleconsultation is appropriate or whether the patient needs to be examined in person. The RMP must also make reasonable efforts to collect sufficient medical information before proceeding.
Similarly, a teleconsultation cannot replace a physical examination that requires palpation, percussion or auscultation. Where such an examination is critical, the RMP should not proceed until it can be arranged, either in person or through another RMP or healthcare worker.
The mode of consultation should be appropriate to the patient’s clinical needs. For instance, an audio consultation may be sufficient where the patient needs to be heard, while video may be necessary where visual assessment is relevant.
Arguably, for many chronic conditions, a diagnosis can be based on the patient’s medical history and objective measurements rather than a physical examination. Diabetes, for example, can be assessed through blood glucose levels and HbA1c reports. Hypertension can be assessed through repeated blood pressure readings, while obesity can be assessed using weight, height and BMI.
Where reliable information is available, including laboratory reports or readings from validated home-monitoring devices, an RMP may be able to arrive at a diagnosis, or at least a provisional diagnosis, through video consultation. This is important because the Guidelines require an appropriate diagnosis or provisional diagnosis before prescribing. Prescribing without it amounts to professional misconduct.
When it comes to diseases like obesity, the difficulty is that not everything can be adequately assessed remotely. Self-reported weight or blood pressure readings may not always be reliable. A remote consultation may also fail to identify underlying complications, symptoms arising due to a secondary cause, or contraindications that would become apparent only through a physical examination.
Can Medicines for a Chronic Condition Be Prescribed Without an In-Person Consultation?
While prescribing medicines via telemedicine is at the professional discretion of an RMP, there are certain limitations on what can be prescribed via telemedicine, depending on the type and mode of consultation.
The Guidelines divide medicines into four categories (List A is shown in two rows below, for first-consultation and follow-up medicines):
Category | What it covers | When it can be prescribed |
List O | Commonly used over-the-counter medicines and medicines notified by the Government for public health emergencies. | Through any mode of teleconsultation, including first and follow-up consultations. |
List A – First Consultation Medication | Medicines considered relatively safe and having a low potential for abuse such as antifungal ointments | During a first consultation, provided it is conducted by video, and during follow-up consultations |
List A – Follow-up medications | Medicines for chronic illnesses | Medicines prescribed for refill when face to face consultation is not necessary, such as Metformin, Glibenclamide, etc. for Diabetes
|
List B | Add-on medicines used to optimise an existing treatment. | Follow-up consultations only. |
Prohibited List | Schedule X drugs and narcotic and psychotropic substances. | Cannot be prescribed through telemedicine. |
While there is no definition of first consult medications and follow-up medications, the Guidelines define a "First Consult" to include a patient consulting an RMP for the first time, a consultation occurring more than six months after the previous consultation, or a consultation concerning a different health condition. Conversely, a "Follow-Up Consult" requires the patient to be consulting the same RMP within six months of the previous in-person consultation, for continuation of care for the same health condition. This distinction is important because the Guidelines contemplate the prescription and renewal of certain chronic-condition medications during follow-up consultations for refill, where a face-to-face consultation is not considered necessary.
4. Implications for GLP-1 medication programmes
These requirements create certain interpretational difficulties for GLP-1 medication programmes, particularly those that operate entirely through telemedicine. Obesity is recognised by the World Health Organization as a chronic disease. Consequently, where GLP-1 medicines are prescribed for the management of obesity, there is a reasonable basis to consider them within the framework governing medicines for chronic conditions i.e., follow-up medication, rather than treating them as ordinary first-consultation medications.
Accordingly, even if it can be argued that obesity can be diagnosed via teleconsultation, a patient who has only ever consulted the RMP remotely may not satisfy the definition of a follow-up consultation under the Guidelines. The concern arises from the limited permissibility of prescribing medicines for chronic conditions for “refill” and, more specifically, the requirement of a previous in-person consultation for a consultation to qualify as a follow-up consultation necessary to prescribe GLP-1 injectables as a refill medication. In turn, this creates a potential limitation for GLP-1 programmes that seek to initiate and continue treatment entirely through remote consultations.
Conclusion
For GLP-1-based programmes in particular, the Telemedicine Guidelines do not expressly classify these medicines under any of the lists. A platform that treats a first-time prescription of a self-administered injectable GLP-1 medicine as falling within List A is therefore relying on an interpretation that may be arguable but is not free from regulatory risk. Platforms and RMPs can reduce this risk by building safeguards into their fully remote chronic-care programmes.